1. Home
  2. ACAD vs BFAM Comparison

ACAD vs BFAM Comparison

Compare ACAD & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Bright Horizons Family Solutions Inc.

BFAM

Bright Horizons Family Solutions Inc.

N/A

Current Price

$50.22

Market Cap

3.6B

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
BFAM
Founded
1993
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.6B
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
ACAD
BFAM
Price
$17.18
$50.22
Analyst Decision
Buy
Hold
Analyst Count
20
9
Target Price
$30.21
★ $71.22
AVG Volume (30 Days)
★ 2.4M
1.4M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.12
40.00
EPS
★ 0.51
N/A
Revenue
$726,437,000.00
★ $1,903,182,000.00
Revenue This Year
$19.55
$4.61
Revenue Next Year
$13.34
$3.80
P/E Ratio
$34.47
★ N/A
Revenue Growth
★ 40.45
N/A
52 Week Low
$15.86
$49.77
52 Week High
$30.96
$105.75

Technical Indicators

Market Signals
Indicator
ACAD
BFAM
Relative Strength Index (RSI) 34.82 29.69
Support Level $15.86 N/A
Resistance Level $22.71 $78.95
Average True Range (ATR) 1.20 1.82
MACD -0.11 -0.21
Stochastic Oscillator 18.38 4.38

Price Performance

Historical Comparison
ACAD
BFAM

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About BFAM Bright Horizons Family Solutions Inc.

Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; Full-service center-based child care, Backup care, and Educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.

Share on Social Networks: